Vera Therapeutics (NASDAQ:VERA) Stock Moved Up to Sell by Wall Street Zen

Wall Street Zen upgraded shares of Vera Therapeutics (NASDAQ:VERA) from a strong sell rating to a sell rating in a research note released on Saturday,Wall Street Zen reports.

A number of other equities analysts have also recently weighed in on the company. JPMorgan Chase & Co. upped their price target on Vera Therapeutics from $76.00 to $83.00 and gave the stock an “overweight” rating in a report on Tuesday, September 8th. Leerink Partners started coverage on shares of Vera Therapeutics in a research note on Monday, October 12th. They set a “market perform” rating and a $34.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Thursday, October 15th. Wedbush decreased their target price on shares of Vera Therapeutics from $34.00 to $29.00 and set a “neutral” rating for the company in a research note on Friday. Finally, TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $74.93.

Vera Therapeutics Trading Down 1.2%

NASDAQ:VERA opened at $29.78 on Friday. The business’s 50-day moving average is $31.60 and its two-hundred day moving average is $36.68. The firm has a market capitalization of $2.15 billion, a PE ratio of -5.05 and a beta of 1.07. Vera Therapeutics has a 12 month low of $23.86 and a 12 month high of $56.05. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.92.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, November 5th. The company reported ($1.30) earnings per share for the quarter, topping the consensus estimate of ($1.62) by $0.32. The company had revenue of $10.28 million during the quarter, compared to analysts’ expectations of $3.42 million. Research analysts predict that Vera Therapeutics will post -6.45 earnings per share for the current fiscal year.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 18,500 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $37.00, for a total value of $684,500.00. Following the completion of the transaction, the chief executive officer owned 235,244 shares of the company’s stock, valued at approximately $8,704,028. This represents a 7.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 15.90% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Pictet Asset Management Holding SA increased its stake in shares of Vera Therapeutics by 47.2% in the third quarter. Pictet Asset Management Holding SA now owns 1,839,245 shares of the company’s stock valued at $59,397,000 after purchasing an additional 589,831 shares during the period. Readystate Asset Management LP bought a new stake in shares of Vera Therapeutics during the second quarter valued at approximately $12,663,000. Renaissance Technologies LLC boosted its position in shares of Vera Therapeutics by 136.5% during the first quarter. Renaissance Technologies LLC now owns 457,300 shares of the company’s stock worth $18,397,000 after buying an additional 263,900 shares during the period. Engineers Gate Manager LP boosted its position in shares of Vera Therapeutics by 1,579.2% during the second quarter. Engineers Gate Manager LP now owns 108,139 shares of the company’s stock worth $4,640,000 after buying an additional 101,699 shares during the period. Finally, Candriam S.C.A. boosted its position in shares of Vera Therapeutics by 21.5% during the third quarter. Candriam S.C.A. now owns 568,560 shares of the company’s stock worth $18,426,000 after buying an additional 100,461 shares during the period. 99.21% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: For Q3 2026, Vera reported a loss of $1.30 per share, narrower than the $1.62 consensus loss, and revenue of $10.28 million versus estimates of $3.42 million. The earnings beats are supportive, although the company remained loss-making. Quarterly earnings report
• Positive Sentiment: HC Wainwright cut its price target to $75 from $90 but maintained a Buy rating. Its revised target still implies substantial upside from the cited $29.79 share price, which may offer support to investors. HC Wainwright rating update
• Neutral Sentiment: Vera granted stock options covering 14,900 shares and restricted stock units covering 7,450 shares to three new employees. The awards are a routine hiring incentive, with a small potential dilution effect. Inducement grants announcement
• Negative Sentiment: A valuation-focused article argues VERA may be above fair value after a 148% run, raising the risk that investors take profits or demand stronger progress to justify the share price. Valuation analysis
• Negative Sentiment: Although HC Wainwright remains bullish, its $15 reduction in the target reflects a more cautious view than before and may temper optimism. HC Wainwright rating update

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company’s research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera’s lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.